Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

U. A. Matulonis, G. M. Wulf, W. T. Barry, M. Birrer, S. N. Westin, S. Farooq, K. M. Bell-McGuinn, E. Obermayer, C. Whalen, T. Spagnoletti, W. Luo, H. Liu, R. C. Hok, C. Aghajanian, D. B. Solit, G. B. Mills, B. S. Taylor, H. Won, M. F. Berger, S. PalakurthiJ. Liu, L. C. Cantley, E. Winer

Research output: Contribution to journalArticlepeer-review

122 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences